Answers are grounded in this paper and cite their sources.
INTRODUCTION: Factor VIII (FVIII) activity remains essential for diagnosing and classifying hemophilia A, conducting pharmacokinetic assessments, guiding perioperative management, and monitoring treatment. However, extended half-life FVIII products, emicizumab, and recently approved and emerging non-factor therapies have revealed important limitations of conventional FVIII activity assays. AREAS COVERED: We conducted a targeted, non-systematic literature search using PubMed/MEDLINE, focusing primarily on publications from 1 September 2011, to 31 August 2026, supplemented by earlier seminal studies and reference-list screening. This review examines the current role and limitations of FVIII activity monitoring, including one-stage clotting and chromogenic assays, assay discrepancies in non-severe hemophilia A, monitoring of standard and extended half-life FVIII products, and laboratory assessment during emicizumab and other non-factor therapies. It also evaluates the potential complementary roles of global coagulation assays, including thrombin generation, clot waveform analysis, and viscoelastic testing. EXPERT OPINION: No single assay addresses every clinical question in contemporary hemophilia A care; FVIII activity measurement remains indispensable, but results must be interpreted according to the treatment, assay principle, reagent system, sampling time, and clinical purpose. An optimal strategy will combine validated FVIII assays with selected global coagulation assays when appropriate, although further standardization and clinical validation are required.
No takes yet. Share an insight, caveat, or question.
Nakajima et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: